HEICO, Dave & Buster’s Entertainment and Healthcare Stocks Insiders Are Buying – Dave & Buster’s Enter (NASDAQ: PLAY ), Heico (NYSE: HEI )

While U.S. stocks closed higher on Wednesday, there were some noteworthy insider trades.

When insiders buy stock, it’s a sign that they have confidence in the company’s prospects, or that they think the stock is a good deal. Either way, this points to an opportunity to be long the stock. Insider buying should not be considered the only indicator in making an investment or trading decision. At best, it can provide confidence in buying decisions.

Here are some recent notable insider trades.For more information, please view Insider trading at Benzinga platform.

Heike

• trading: Haike Company here Director Frank Schwitters A total of 1,385 shares were acquired The average price is $157.07. The cost of acquiring these shares was approximately $217,540.
• what happened: The company reported upbeat quarterly results last month.
• What HEICO does: Heico is an aerospace and defense supplier primarily focused on manufacturing niche replacement parts for commercial aircraft and components for defense products.

Dave and Buster’s Entertainment

• trading: dave and buster entertainment Play Ashley Zickefoose, Senior Vice President and Chief Marketing Officer Acquired a total of 3,600 shares The average price is $41.58. The cost of acquiring these shares was approximately $149,680.
• what happened: The company reported quarterly earnings online last month.
• Dave & Buster’s Entertainment’s business: Dave & Buster’s Entertainment Inc owns and operates nearly 100 entertainment and dining venues in the United States where patrons can eat, drink, play games and watch televised sports.

Don’t forget to check out our Pre-launch coverage here

Take a look at this: Netflix stock up around 18%?Here are 10 other analyst forecasts for Thursday

TC Biopharmaceuticals

• trading: TC Biopharmaceutical (Holdings) Co., Ltd. TCBP 10% Owner Edward Mark Randall A total of 70,000 shares were bought The average price is $5.00. The cost of acquiring these shares was approximately $350,000.
• what happened: TC BioPharm reported 1H EPS of $1.13 last month.
• What TC Biopharm does: TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic products based on its proprietary allogeneic γδT (abbreviated as GD-T) cell platform.